Share on StockTwits

Regeneron Pharmaceuticals (NASDAQ:REGN) VP Douglas S. Mccorkle sold 5,875 shares of the company’s stock on the open market in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $353.00, for a total value of $2,073,875.00. Following the transaction, the vice president now directly owns 3,000 shares of the company’s stock, valued at approximately $1,059,000. The transaction was disclosed in a document filed with the SEC, which is available at this link.

A number of analysts have recently weighed in on REGN shares. Analysts at RBC Capital raised their price target on shares of Regeneron Pharmaceuticals from $349.00 to $373.00 in a research note on Wednesday, August 6th. They now have an “outperform” rating on the stock. Separately, analysts at Roth Capital reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, August 5th. Finally, analysts at Deutsche Bank raised their price target on shares of Regeneron Pharmaceuticals from $410.00 to $425.00 in a research note on Tuesday, August 5th. They now have a “buy” rating on the stock. Five research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $345.94.

Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 0.24% during mid-day trading on Monday, hitting $349.46. 509,857 shares of the company’s stock traded hands. Regeneron Pharmaceuticals has a 52 week low of $227.64 and a 52 week high of $352.49. The stock has a 50-day moving average of $316. and a 200-day moving average of $308.5. The company has a market cap of $35.082 billion and a P/E ratio of 99.21.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings data on Tuesday, August 5th. The company reported $2.47 earnings per share for the quarter, beating the analysts’ consensus estimate of $2.30 by $0.17. The company had revenue of $666.00 million for the quarter, compared to the consensus estimate of $647.99 million. During the same quarter last year, the company posted $1.73 earnings per share. Regeneron Pharmaceuticals’s revenue was up 45.4% compared to the same quarter last year. On average, analysts predict that Regeneron Pharmaceuticals will post $10.14 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.